Arizona State University

University of Virginia Patent Foundation

Wofor Ag

Edison Pharmaceuticals, Inc.

Pinnacle Pharmaceuticals, Inc.

Massachusetts Institute of Technology

Other

Wisconsin Alumni Research Foundation

Smithkline Beecham Corporation

Arizona Board of Regents, a Body Corporate

Ptc Therapeutics, Inc.

Bioelectron Technology Corporation

Innovative Biologics, Inc.

Sidney M Hecht

Omar Khdour

Sandipan Roy Chowdhury

Guy M Miller

Rakesh Paul

Arnaud Chevalier

Shengxi Chen

Yung Chang

Xiaowei Liu

Indrajit Bandyopadhyay

Larisa (Liza) Dedkova

Rumit Maini

Yanmin Zhang

Viswanath Arutla

Manikandadas Mathilakathu Madathil

Sriram Sokalingam

Joseph Leal

Paul Mollard

Kieron E Wesson

David Joseph Maloney

Orion D Jankowski

Poulami Talukder

Deborah A Lannigan-Macara

Jeffrey Allan Smith

Nour Eddine Fahmi

Samir D Roy

George Bonneville

Vladimir Karginov

Noureddine Fahmi

Nishant P Visavadiya

Chandrabali Bhattacharya

Jeffrey Charles Boehm

Michael James Rishel

Randall K Johnson

Ulrich Jordis

William D Kingsbury

Frank Schmidtmann

Pablo Arce

Michael Kenneth Hilinski

Xiaoqing Cai

Jose I Armendariz Guajardo

Jun Liu

George A O'Doherty

Jun Lu

Mohammad Alam

Sriloy Dey

Yana Chen

Andrei V Karginov

Michiel Lodder

Edward Locke

Kenneth G Holden

Trevor Bozeman

Folke Skoog

Ruth Y Schmitz

Zhiqiang Yu

Robert B Frye

John W Kozarich

Chenhong Tang

David G Lynn

Kalakota S Reddy

Ryan Schmaltz

Larisa Dedkova

Xiaoguang Bai

Krystal Tsosie

Indrajit Bandyopadhay

Jeffrey Armstrong

David Maloney

The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein Rhas any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as cytoprotective agents.

Mitochondrial therapeutic agents

Provided herein are therapeutic agents having specificity for having inhibitory activity against cancer cells that overexpress human epidermal growth factor receptor (HER) genes, including therapeutic agents comprising one or more HER-targeting peptides, pharmaceutical compositions comprising such therapeutic agents, and methods of using such compositions to treat or prevent a cancer or other disease condition associated with HER overexpression.

DNA-affibody-drug nanoparticles for inhibiting the metastasis of cancer cells overexpressing HER2

Modified ribosomes that were selected using a dipeptidyl-puromycin aminonucleoside are used to mediate site-specific incorporation of one or more peptides and peptidomimetics into protein in a cell free translation system. In addition, new fluorescent dipeptidomimetics have been synthesized and incorporated into proteins, as well as modified proteins containing one or more non-naturally occurring dipeptides.

Ribosome-mediated incorporation of peptides and peptidomimetics

Compositions and methods relating to bacterial ribosomes selected to increase the incorporation of at least one glycosylated amino acid into a protein versus a wild-type bacterial ribosome. Selection embodiments include growing bacteria in the presence of a puromycin derivative, wherein a surviving clone has a ribosome that incorporates at least one glycosylated amino acid into a protein.

Engineered bacterial ribosome compositions and methods

Provided herein are methods for rational design of nicotine haptens. More particularly, provided herein are methods for designing, selecting, and synthesizing nicotine haptens and nicotine hapten conjugates. Also provided herein are novel nicotine haptens and methods for using nicotine haptens to treat nicotine addiction.

Methods of rational nicotine hapten design and uses thereof

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R, R, R, R, subscript m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Therapeutic compounds

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R, R, Rand Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. 

Substituted pyrimidine compounds as multifunctional radical quenchers and their uses

The present invention relates to the use of prodrugs susceptible to nitroreductase (NTR) activation. In particular, provided herein are mitochondria-targeting prodrug compounds and probes, including profluorescent near-infrared (NIR) probes and non-fluorescent prodrugs, as well as to methods of using said prodrug compounds and probes for imaging mitochondria and for mitochondria-specific delivery of therapeutic agents.

Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting

The invention provides compounds formula (I) and salts thereof:  wherein R, R, R, Rand Y have any of the values defined in the specification. The compounds are useful for treatment or suppression of diseases associated with decreased mitochondrial function resulting in diminished ATP production and/or oxidative stress and/or lipid peroxidation.

Substituted phenothiazines as mitochondrial agents

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R, R, R, R, subscipt m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The present invention relates to the use of prodrugs susceptible to nitroreductase (NTR) activation. In particular, provided herein are mitochondria-targeting prodrug compounds and probes, including profluore scent near-infrared (NIR) probes and non-fluorescent prodrugs, as well as to methods of using said prodrug compounds and probes for imaging mitochondria and for mitochondria-specific delivery of therapeutic agents.

Growing community of inventors

Charlottesville, VA, United States of America

Sidney M Hecht